1. Home
  2. SNGX vs AMBO Comparison

SNGX vs AMBO Comparison

Compare SNGX & AMBO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • SNGX
  • AMBO
  • Stock Information
  • Founded
  • SNGX 1987
  • AMBO 2000
  • Country
  • SNGX United States
  • AMBO United States
  • Employees
  • SNGX N/A
  • AMBO N/A
  • Industry
  • SNGX Biotechnology: Pharmaceutical Preparations
  • AMBO Other Consumer Services
  • Sector
  • SNGX Health Care
  • AMBO Real Estate
  • Exchange
  • SNGX Nasdaq
  • AMBO Nasdaq
  • Market Cap
  • SNGX 7.4M
  • AMBO 7.2M
  • IPO Year
  • SNGX 1987
  • AMBO 2010
  • Fundamental
  • Price
  • SNGX $2.34
  • AMBO $2.63
  • Analyst Decision
  • SNGX
  • AMBO
  • Analyst Count
  • SNGX 0
  • AMBO 0
  • Target Price
  • SNGX N/A
  • AMBO N/A
  • AVG Volume (30 Days)
  • SNGX 620.7K
  • AMBO 127.9K
  • Earning Date
  • SNGX 03-14-2025
  • AMBO 12-30-2024
  • Dividend Yield
  • SNGX N/A
  • AMBO N/A
  • EPS Growth
  • SNGX N/A
  • AMBO N/A
  • EPS
  • SNGX N/A
  • AMBO N/A
  • Revenue
  • SNGX $364,183.00
  • AMBO $7,839,000.00
  • Revenue This Year
  • SNGX N/A
  • AMBO N/A
  • Revenue Next Year
  • SNGX $76.64
  • AMBO N/A
  • P/E Ratio
  • SNGX N/A
  • AMBO N/A
  • Revenue Growth
  • SNGX N/A
  • AMBO N/A
  • 52 Week Low
  • SNGX $0.32
  • AMBO $1.00
  • 52 Week High
  • SNGX $14.83
  • AMBO $6.30
  • Technical
  • Relative Strength Index (RSI)
  • SNGX 36.12
  • AMBO 56.53
  • Support Level
  • SNGX $2.23
  • AMBO $2.30
  • Resistance Level
  • SNGX $2.39
  • AMBO $2.90
  • Average True Range (ATR)
  • SNGX 0.17
  • AMBO 0.32
  • MACD
  • SNGX 0.01
  • AMBO 0.02
  • Stochastic Oscillator
  • SNGX 22.12
  • AMBO 79.00

About SNGX Soligenix Inc.

Soligenix Inc is a late-stage biopharmaceutical company based in the United States. It focuses on developing and commercializing products to treat rare diseases where there is an unmet medical need. The company operates through two business segments namely Specialized BioTherapeutics and Public Health Solutions. It generates maximum revenue from Public Health Solutions with active development programs for RiVax, its ricin toxin vaccine candidate, SGX943, its therapeutic candidate for antibiotic resistant and emerging infectious disease, and its research programs to identify and develop novel vaccine candidates targeting viral infection including Ebola, Marburg and SARS-CoV-2 (the cause of COVID-19).

About AMBO Ambow Education Holding Ltd.

Ambow Education Holding Ltd is a provider of educational and career enhancement services in China. It operates through CP&CE Programs. The CP&CE Programs include tutoring services and career enhancement services. Geographically all the operations function in the United States and Foreign countries.

Share on Social Networks: